InxMed

InxMed is a Chinese clinical-stage biotechnology company focused on developing treatments for difficult-to-treat solid tumors that are currently drug-resistant and are especially resistant to anti-PD-1/PD-L1 (programmed cell death protein and programmed death-ligand known to suppress the immune system ) anti-cancer drugs. The company has set up a global translational medicine and clinical development team across China, the US, Canada, and Australia. 

Its lead drug candidate, IN10018, is a small molecule focal adhesion kinase (FAK) protein inhibitor for treating multiple cancers including platinum-resistant ovarian cancer (resistance to first-line platinum-based chemotherapy), NRAS-mutant melanoma (skin cancer), and KRAS-mutant solid tumors. It began its Phase Ib clinical study of IN10018 for treating NRAS-mutant metastatic melanoma in the US in 2020 and the FDA granted IN10018 fast-track designation as a treatment for platinum-resistant ovarian cancer in August 2021 based on preliminary efficacy data. As of March 2022, the company was studying the drug in Phase I/II clinical trial and plans to initiate pivotal trials of the drug in the same year. Other drug candidates in its pipeline include treatments for cancer-associated fibroblast (CAF) mutation (known to support tumor cell growth) and Tyro3, Axl, and MerTK (TAM) mutation in solid tumors, along with an agent targeting epigenetic regulation. Its drug pipeline consists of four compounds. As of March 2022, it had partnerships with Roche, Boehringer Ingelheim, and MSD. 

In March 2022, the company raised USD 50 million in a Series B funding round led by CS Capital which will be used to fund pivotal clinical trials of IN10018 in the US and China as well as to launch trials for other therapeutic treatments in its pipeline and improve its R&D capabilities in China. The company later secured an additional USD 15 million in a Series B extension from Hyfinity Investments in May 2022.